Biotechnology


LEUVEN, Belgium and LUND, Sweden, December 16, 2011 - ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce today that they have completed the enrolment of a 632-patient Phase IIb trial with their novel long-acting anticoagulant TB-402 (factor VIII inhibitor) for the prophylaxis of venous thromboembolism (VTE) after total hip surgery.

AMSTERDAM, December 15, 2011 - Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the Company has a negative equity position, as a result of ongoing loss-making operations.

MUNICH, December 15, 2011 - Highly advanced surgical navigation system to enable faster, more precise and safer surgery This week, university hospital Klinikum rechts der Isar in Munich, Germany, is the first hospital in the world to operate with Brainlab's Curve™ Image Guided Surgery system.

BOSTON, December 15, 2011 - Enlight Biosciences LLC announced today that it has formed new partnerships with AstraZeneca and Novo Nordisk.As partners in Enlight, AstraZeneca and Novo Nordisk will have the opportunity to collaborate and invest in the development of potentially transformational technologies with application to their therapeutic programs. Enlight was created by PureTech Ventures in partnership with major pharmaceutical companies and academic luminaries to proactively address critical unmet industry needs.
Older News
S M T W T F S
28 29 30 31 1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
Copyright© 2011 The Gaea Times